Publications by authors named "Itziar Arrieta Aldea"
Introduction: People with HIV (PWH) with poor immune response despite adequate antiretroviral treatment (ART) are susceptible to non-AIDS-related health issues. This study seeks to evaluate bone quality in Immunological Non-Responders (INRs) in comparison to those with proper immune response (IRs) using in vivo microindentation to quantify bone quality, in addition to conventional bone mineral density (BMD) evaluations.
Methods: A cross-sectional study was conducted at Hospital del Mar in Barcelona from January 2019 to June 2023.
Article Synopsis
- The ongoing Monkeypox virus outbreak primarily affects individuals living with HIV, and this study focuses on their immune response after receiving the JYNNEOS smallpox vaccine.
- The vaccine was administered safely via intradermal (i.d.) and subcutaneous (s.c.) methods, with i.d. vaccination showing better T-cell response and polyfunctionality.
- HIV-1-infected individuals with lower CD4 T-cell counts needed a booster shot for effective immune response, and the strength of their Th1 response was linked to their CD4 T-cell levels, highlighting the need for further research.
Background: This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH).
Methods: The retrospective study conducted from April 2019 to November 2022, included PLWH with < 50 copies/mL of HIV-RNA prior to recruitment who initiated either D/L or B/F/T switching therapy. The primary objective was to evaluate treatment discontinuation rates; safety and virologic outcomes were also evaluated.
Background: The impact of tenofovir disoproxil fumarate (TDF) antiretroviral (ART) regimens on bone health has been characterized mostly by bone mineral density (BMD), but recently also by bone quality (BQ). The aim of this pilot study is to assess the changes in BMD and BQ after switch from TDF to tenofovir alafenamide (TAF) ART.
Methods: HIV individuals receiving TDF-based ART were randomized to switch to Bictegravir-TAF-Emtricitabine or to remain in the same regimen.
Article Synopsis
- Long-term non-progressors (LTNPs) are HIV+ individuals whose viral replication is controlled but still face complications like bone remodeling impairment.
- A study measured bone strength components and inflammatory biomarkers among LTNPs, HIV+ progressors, and HIV-negative individuals, revealing that LTNPs had lower bone material strength (BMSi) and a distinct inflammatory profile.
- The findings indicate that LTNPs experience worse bone tissue quality compared to both HIV+ progressors and HIV-negative individuals, suggesting a broader impact of HIV infection on bone health.
Article Synopsis
- A study compared clinical characteristics and outcomes of patients with COVID-19 and seasonal influenza who needed supplemental oxygen, focusing on factors like age, comorbidities, and mortality rates.
- COVID-19 patients were generally younger but had more severe symptoms, including higher pneumonia rates and worse progression, leading to a significantly higher 30-day mortality rate of 15% compared to 5% for influenza patients.
- Additionally, COVID-19 patients experienced longer hospital stays and higher costs related to critical care and treatments compared to those with seasonal influenza.
Article Synopsis
- The study investigates neurocognitive impairment (NI) and frailty in older adults living with HIV, focusing on risk factors associated with these conditions.
- Conducted with 40 HIV-positive individuals aged over 65 in Barcelona, it used clinical assessments and blood testing to measure NI and frailty.
- Results revealed that low education level, a nadir CD4+ T-cell count below 350 cells/mm, and the presence of comorbidities (especially diabetes) significantly increased the risk of neurocognitive disorders in this population.
Objectives: SARS-CoV-2 infection induces virus-reactive memory B cells expressing unmutated antibodies, which hints at their emergence from naïve B cells. Yet, the dynamics of virus-specific naïve B cells and their impact on immunity and immunopathology remain unclear.
Methods: We longitudinally profiled SARS-CoV-2-specific B-cell responses in 25 moderate-to-severe COVID-19 patients by high-dimensional flow cytometry and isotyping and subtyping ELISA.
Background: Bone mineral density (BMD) decreases with ART initiation with a tenofovir disoproxil fumarate-containing regimen, although bone tissue quality increases. The impact of dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC)-based ART initiation on bone health parameters is not clear.
Objectives: To study the impact of DTG/ABC/3TC-based therapy on bone health parameters in ART-naive individuals with HIV after 48 weeks of treatment.